Kintara Therapeutics (KTRA) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Kintara Therapeutics has corrected its previous announcement regarding the issuance of Contingent Value Rights (CVRs) related to its planned merger with TuHURA Biosciences. The CVRs will now be issued to stockholders immediately before a planned reverse stock split, aligning with the upcoming merger scheduled for October 18, 2024.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.
